Christophe Massard

Christophe Massard

UNVERIFIED PROFILE

Are you Christophe Massard?   Register this Author

Register author
Christophe Massard

Christophe Massard

Publications by authors named "Christophe Massard"

Are you Christophe Massard?   Register this Author

100Publications

6232Reads

-Profile Views

Exploring the optimal use of alectinib.

Lancet Respir Med 2019 May 15;7(5):373-374. Epub 2019 Apr 15.

Cancer Medicine Department, Gustave Roussy Cancer Center, F-94805, Villejuif, France; University Paris-Sud, Faculty of Medicine, Le Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30117-1DOI Listing
May 2019

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential.

Onco Targets Ther 2019 3;12:2505-2512. Epub 2019 Apr 3.

Drug Development Department, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S141040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452813PMC
April 2019

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Lancet Haematol 2019 Jan 4;6(1):e48-e57. Epub 2018 Dec 4.

Service de Médecine Interne and Immunologie Clinique, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France; Université Paris Sud, Centre de Recherche en Immunologie des Infections Virales et des Maladies Auto-Immunes, INSERM, Le Kremlin-Bicêtre, France; Division d'Immunovirologie, Commissariat à l'Energie Atomique et aux Energies Alternatives, Fontenay-aux-Roses, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30175-3DOI Listing
January 2019

A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment.

Clin Genitourin Cancer 2019 Jan 26. Epub 2019 Jan 26.

Department of Cancer Medicine, Gustave Roussy, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.010DOI Listing
January 2019

Hyperprogressive disease: recognizing a novel pattern to improve patient management.

Nat Rev Clin Oncol 2018 12;15(12):748-762

Département d'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0111-2
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0111-2DOI Listing
December 2018

Focus on the Number of Radiation Oncology Trials or on Clinical Relevance?

JAMA Oncol 2018 Dec;4(12):1791

Faculté de médecine Paris Sud, Université Paris Sud, Université Paris Saclay, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.5116DOI Listing
December 2018

Cancer du rein : tendances et perspectives.

Bull Cancer 2018 Dec;105 Suppl 3:S219-S220

Département de radiothérapie, institut de cancérologie Lucien-Neuwirth 108 bis, avenue Albert-Raimond, BP 60008, 42270 Saint-Priest-en-Jarez, cedex, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(18)30375-8DOI Listing
December 2018

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

Eur J Cancer 2018 11 14;103:108-119. Epub 2018 Sep 14.

Department of Interventional Radiology, Gustave Roussy, Villejuif, France; Faculté de Médecine, Kremlin-Bicêtre, Université Paris Sud, France; Laboratory of Translational Research in Immunology - LRTI, INSERM U1015, Gustave Roussy, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.08.003DOI Listing
November 2018

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Lancet Oncol 2018 09 14;19(9):1180-1191. Epub 2018 Aug 14.

Gustave Roussy-CentraleSupélec-Therapanacea Centre of Artificial Intelligence in Radiation Therapy and Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Radiomics Team, Molecular Radiotherapy INSERM U1030, Paris-Sud University, Gustave Roussy Cancer Campus, and University of Paris-Saclay, Villejuif, France; Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30413-3DOI Listing
September 2018

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.

Eur Urol Focus 2018 Sep 4. Epub 2018 Sep 4.

Drug Development Department (DITEP), Inserm Unit U981, Université Paris Saclay, Université Paris-Sud, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2018.08.022DOI Listing
September 2018

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.

J Immunother Cancer 2017 18;5:31. Epub 2017 Apr 18.

Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0232-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394619PMC
June 2018

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

J Clin Oncol 2018 May 7:JCO2018782292. Epub 2018 May 7.

Jeremy Lewin and Lillian L. Siu, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Jean-Charles Soria and Christophe Massard, Institut Gustave Roussy and University Paris-Sud, Villejuif; Jean-Pierre Delord, Institut Claudius Regaud Oncopole, Toulouse; Mohamed Bekradda, Oncology Therapeutic Development, Clichy; Keyvan Rezai, Hôpital René Huguenin, Saint-Cloud, France; Anastasios Stathis, Oncology Institute of Southern Switzerland, Bellinzona; Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Ahmad Awada and Philippe G. Aftimos, Université Libre de Bruxelles, Brussels, Belgium; and Zhen Zeng, Azher Hussain, and Susan Perez, Merck & Co, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2292DOI Listing
May 2018

Durvalumab in urothelial cancers.

Expert Rev Anticancer Ther 2018 04 5;18(4):311-318. Epub 2018 Mar 5.

b Drug Development Department (DITEP), Gustave Roussy , Université Paris-Sud, Université Paris-Saclay , Villejuif , France.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737140.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737140.2018.1443812DOI Listing
April 2018

Are phase I trials safe for older patients?

J Geriatr Oncol 2018 03 8;9(2):87-92. Epub 2017 Sep 8.

Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif Cedex F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2017.08.012DOI Listing
March 2018

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Eur J Cancer 2018 03 10;91:21-29. Epub 2018 Jan 10.

Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, F-94275, Le Kremlin-Bicêtre, France; INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276, Le Kremlin-Bicêtre, France; Université Paris Sud, UMR 1184, F-94276, Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265, Fontenay-aux-Roses, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.008DOI Listing
March 2018

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Eur J Cancer 2018 03 3;92:1-10. Epub 2018 Feb 3.

Drug Development Department, Gustave Roussy, Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France; Gustave Roussy Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.020DOI Listing
March 2018

[Atezolizumab (Tecentriq): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma].

Bull Cancer 2018 Feb 28;105(2):140-145. Epub 2017 Dec 28.

University of Paris Sud, Gustave Roussy cancer campus, drug development department, 94805 Villejuif cedex, France; University of Paris Sud, Gustave Roussy cancer campus, department of medical oncology, 94805 Villejuif cedex, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551173038
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2017.10.030DOI Listing
February 2018

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Clin Genitourin Cancer 2017 12 12;15(6):e1081-e1088. Epub 2017 Aug 12.

Department of Medical Oncology, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.015DOI Listing
December 2017

A polymorphous bullous dermatosis.

Lancet Oncol 2017 12;18(12):e776

Department of Dermatology, Assistance Publique - Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30461-8DOI Listing
December 2017

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Eur J Cancer 2017 10 18;84:202-211. Epub 2017 Aug 18.

Drug Development Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.033DOI Listing
October 2017

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Eur J Cancer 2017 09 22;83:185-193. Epub 2017 Jul 22.

Drug Development Department (DITEP), Gustave Roussy, 94805, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Orsay, 91405, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.016DOI Listing
September 2017

[The breakthrough of personalized medicine, new hopes and new challenges].

Bull Cancer 2017 Sep 12;104(9):735-743. Epub 2017 Aug 12.

Institut Jean-Godinot, département d'oncologie médicale, 51100 Reims, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.07.003DOI Listing
September 2017

The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.

Genet Med 2017 06 1;19(6):683-690. Epub 2016 Dec 1.

Gustave Roussy, Service de Biostatistique et d'Epidémiologie, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/gim.2016.174DOI Listing
June 2017

First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.

Bull Cancer 2017 Jun 5;104(6):552-558. Epub 2017 Apr 5.

Centre Oscar-Lambret, medical oncology department, 3, rue F.-Combemale, 59020 Lille, France; SIRIC ONCOLille Consortium, Clinical Research and Methodology Platform, 59000 Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.02.002DOI Listing
June 2017

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Cancer Chemother Pharmacol 2017 Jun 19;79(6):1257-1265. Epub 2017 Apr 19.

Drug Development Department (DITEP), Gustave Roussy Cancer Centre, Université Paris-Saclay, 114 Rue Eduard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3303-zDOI Listing
June 2017

Patient-reported tolerability of adverse events in phase 1 trials.

ESMO Open 2017 23;2(2):e000148. Epub 2017 Jun 23.

Drug Development department (DITEP), Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519806PMC
June 2017

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Clin Cancer Res 2017 04 8;23(8):1920-1928. Epub 2016 Nov 8.

Département d'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2016/11/
Web Search
http://dx.doi.org/10.1158/1078-0432.CCR-16-1741DOI Listing
April 2017

[Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].

Bull Cancer 2017 Apr 23;104(4):370-379. Epub 2017 Feb 23.

University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department and Department of Medical Oncology, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.01.009DOI Listing
April 2017

Otorhinolaryngological Toxicities of New Drugs in Oncology.

Adv Ther 2017 04 17;34(4):866-894. Epub 2017 Mar 17.

Department of Drug Development (DITEP), Gustave Roussy Cancer Center and School of Medicine, Paris Sud University, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-017-0512-0DOI Listing
April 2017

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

Invest New Drugs 2017 02 25;35(1):79-86. Epub 2016 Oct 25.

Clinical Pharmacology, Henri Mondor Teaching Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Assistance Publique - Hôpitaux de Paris, 94000, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0402-3DOI Listing
February 2017

[Consortium for detection and management of lung damage induced by bleomycin].

Bull Cancer 2016 Jul-Aug;103(7-8):651-61. Epub 2016 May 27.

Gustave-Roussy, département de médecine oncologique, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris Descartes, UFR des sciences pharmaceutiques et biologiques, 75270 Paris cedex 06, France; Gustave-Roussy, département des innovations thérapeutiques et des essais précoces, 114, rue Édouard-Vaillant, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.04.005DOI Listing
January 2017

[Standard of care of carcinomas on cancer of unknown primary site in 2016].

Bull Cancer 2016 Jul-Aug;103(7-8):697-705. Epub 2016 Jun 29.

Gustave-Roussy Cancer Campus, département d'oncologie médicale, 114, rue Édouard-Vaillant, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.05.003DOI Listing
January 2017

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.

Eur J Cancer 2016 12 4;69:151-157. Epub 2016 Nov 4.

Department of Cancer Medicine, Institut Gustave Roussy, Université Paris-Sud, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.10.003DOI Listing
December 2016

Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.

Eur Urol Focus 2016 Dec 3;2(5):547-552. Epub 2016 Feb 3.

Department of Translational Medicine Division of Urological Cancers, Malmö, Lund University, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.01.005DOI Listing
December 2016

Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.

Eur J Cancer 2016 11 17;68:156-162. Epub 2016 Oct 17.

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; DITEP, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; University Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.09.013DOI Listing
November 2016

[Localized prostate cancer: Changes are still expected].

Bull Cancer 2016 Oct;103(10):809-810

Centre Antoine-Lacassagne, département de radiothérapie, 33, avenue Valombrose, 06189 Nice, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.09.015DOI Listing
October 2016

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

J Clin Oncol 2016 09 6;34(26):3119-25. Epub 2016 Jun 6.

Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.9761DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569690PMC
September 2016

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Eur J Cancer 2016 09 21;65:33-42. Epub 2016 Jul 21.

Université Paris-Saclay, Paris, France; Gustave Roussy, Université Paris-Saclay, Drug Development Department, Villejuif, F-94805, France; Gustave Roussy, Université Paris-Saclay, INSERM U981, Predictive Biomarkers and New Therapeutic Strategies in Oncology, Villejuif, F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.05.031DOI Listing
September 2016

Safety of available treatment options for renal cell carcinoma.

Expert Opin Drug Saf 2016 Aug 23;15(8):1097-106. Epub 2016 May 23.

a Gustave Roussy Cancer Campus.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2016.1184643DOI Listing
August 2016

Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.

Eur J Cancer 2016 07 3;61:44-51. Epub 2016 May 3.

Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.03.070DOI Listing
July 2016

Emerging circulating biomarkers in glioblastoma: promises and challenges.

Expert Rev Mol Diagn 2015 ;15(10):1311-23

c 3 AP-HP, Hôpital Universitaire la Pitié Salpêtrière, Service de Neurologie 2-Mazarin, F-75013, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737159.2015.1087315DOI Listing
June 2016

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.

Clin Cancer Res 2016 06 12;22(12):2960-8. Epub 2016 Jan 12.

Laboratoire de Recherche Translationnelle et Centre de RessourcesBiologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France. INSERM U981, Gustave Roussy, Villejuif, France. Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, France. Faculté de Pharmacie, Université Paris Sud, Châtenay-Malabry, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2470DOI Listing
June 2016

[ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies].

Bull Cancer 2016 Jun 24;103(6):594-603. Epub 2016 May 24.

AERIO, 149, avenue du Maine, 75014 Paris, France; DITEP, Gustave-Roussy, 94805 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.04.001DOI Listing
June 2016

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.

Expert Rev Anticancer Ther 2015 ;15(9):1007-17

a Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 114 rue Edouard Vaillant, 94800 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2015.1081566DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554PMC
May 2016

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

Bull Cancer 2016 May 28;103(5):484-98. Epub 2016 Mar 28.

Institut Gustave-Roussy, département de radiothérapie, 114, rue Édouard-Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.02.014DOI Listing
May 2016

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

J Clin Oncol 2016 Mar 11;34(8):833-42. Epub 2016 Jan 11.

David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Jeffrey A. Sosman, Vanderbilt University School of Medicine; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Mario Sznol, Yale Cancer Center, New Haven, CT; Christophe Massard, Gustave Roussy, Villejuif Cedex, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Omid Hamid, Angeles Clinic and Research Institute, Santa Monica; Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hedge, and Gregg D. Fine, Genentech, South San Francisco, CA; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; and Thomas Powles, Barts Cancer Institute Centre for Experimental Cancer Medicine and the Royal Free National Health Service Trust, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.7421DOI Listing
March 2016

Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma.

Clin Genitourin Cancer 2016 Feb 17;14(1):e91-3. Epub 2015 Aug 17.

Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.07.014DOI Listing
February 2016

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

J Thorac Oncol 2016 Feb 18;11(2):e21-3. Epub 2015 Dec 18.

DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France; Faculté de médicine Paris-Sud XI, Kremlin-Bicêtre, France; U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.08.001DOI Listing
February 2016

[2015 through the eyes of the Bulletin of Cancer editorial board].

Bull Cancer 2016 Jan 15;103(1):3-17. Epub 2016 Jan 15.

Hôpitaux de Chartres, service oncologie hématologie, , site Louis-Pasteur, 28630 Chartres-Le-Coudray, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2015.11.006DOI Listing
January 2016

[Nivolumab, a new hope in non-small cell lung cancer].

Bull Cancer 2015 Dec 14;102(12):1046-52. Epub 2015 Nov 14.

Hôpital Louis-Pasteur, service d'oncologie et hématologie, 28630 Chartres-Le-Coudray, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2015.10.005DOI Listing
December 2015